Skip to main navigation
Logo

Live - Corprorate Menu

  • About Us
    • Our Leadership
    • Diversity, Equity, and Inclusion
    • Collaborations
    • Compliance and Ethics
    • Corporate Giving
  • Our Focus
    • Cerebral Adrenoleukodystrophy
    • Sickle Cell Disease
    • Transfusion Dependant Beta-Thalassemia
  • Our Science
    • Our Approach to Gene Therapy
    • Our Treatment Process
    • Our Pipeline
    • Clinical Trials
  • Patients & Advocacy
    • Patient Advocacy
    • Patient Resources
    • Access Policy

Live - Top Nav

  • investors & media
  • contact us
  • careers
  • stories

Investors & Media

Overview Corporate Governance Press Releases Events & Presentations Analyst Coverage Stock Information SEC Filings Investor FAQs

Toolkit

  • Annual Meeting
  • Information Request
  • Sign Up for Email Alerts
  • RSS Feeds

Media Contacts

  • Sarah Alspach

    Chief Communications Officer

    (857) 299-6198

    sarah.alspach@bluebirdbio.com

  • Jess Rowlands

    Senior Director, Product Communications

    (857) 299-6103

    jess.rowlands@bluebirdbio.com

Investor Contacts

  • Courtney O’Leary

    Investor Relations

    (978) 621-7347

    coleary@bluebirdbio.com

bluebird bio Announces Data Demonstrating First Four Patients with β-Thalassemia Major Treated with LentiGlobin™ are Transfusion-Free

  • Read more about bluebird bio Announces Data Demonstrating First Four Patients with β-Thalassemia Major Treated with LentiGlobin™ are Transfusion-Free

bluebird bio Reports Fiscal Third Quarter 2014 Financial Results

  • Read more about bluebird bio Reports Fiscal Third Quarter 2014 Financial Results

James M. DeTore joins bluebird bio as Chief Financial Officer

  • Read more about James M. DeTore joins bluebird bio as Chief Financial Officer

bluebird bio to Present at Three Upcoming Health Care Conferences

  • Read more about bluebird bio to Present at Three Upcoming Health Care Conferences

bluebird bio to Present LentiGlobin Clinical Data at the American Society of Hematology Conference

  • Read more about bluebird bio to Present LentiGlobin Clinical Data at the American Society of Hematology Conference

bluebird bio Announces First Patient with Sickle Cell Disease Transplanted with LentiGlobin Gene Therapy

  • Read more about bluebird bio Announces First Patient with Sickle Cell Disease Transplanted with LentiGlobin Gene Therapy

bluebird bio to Present at Morgan Stanley Global Health Care Conference

  • Read more about bluebird bio to Present at Morgan Stanley Global Health Care Conference

bluebird bio Reports Fiscal Second Quarter 2014 Financial Results

  • Read more about bluebird bio Reports Fiscal Second Quarter 2014 Financial Results

bluebird bio to Present at Two Upcoming Health Care Conferences

  • Read more about bluebird bio to Present at Two Upcoming Health Care Conferences

bluebird bio Appoints Mark Vachon to its Board of Directors

  • Read more about bluebird bio Appoints Mark Vachon to its Board of Directors

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 32
  • Page 33
  • Page 34
  • Page 35
  • Current page 36
  • Page 37
  • Page 38
  • Page 39
  • Page 40
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Quick Links

  • Patients & Advocacy
  • Investors & Media
  • Careers
  • Contact Us

CONTACT INFO

info@bluebirdbio.com

clinicaltrials@bluebirdbio.com

investor@bluebirdbio.com

medinfo@bluebirdbio.com

Live - Terms & Privacy

  • Terms of Service
  • Privacy Policy
  • Cookie Notice
  • Sitemap
© 2022 bluebird bio, Inc. All Rights Reserved. Corp-US-00175 04/22

Live - Social Links